.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,939,654

« Back to Dashboard

Details for Patent: 7,939,654

Title:Platelet derived growth factor (PDGF) nucleic acid ligand complexes
Abstract: This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jul 30, 2009
Application Number:12/512,780
Claims:1. A complex comprising a platelet derived growth factor (PDGF) nucleic acid ligand of SEQ ID NO:146 and a non-immunogenic, high molecular weight compound, wherein N at positions 10 and 23 of SEQ ID NO:146 is ##STR00002##

2. The complex of claim 1, wherein the non-immunogenic, high molecular weight compound is a polyalkylene glycol.

3. The complex of claim 2, having one or more polyalkylene glycols.

4. The complex of claim 3, wherein each of the one or more polyalkylene glycols is polyethylene glycol.

5. The complex of claim 4, wherein the polyethylene glycol has a molecular weight of about 10-80K.

6. The complex of claim 5, wherein the polyethylene glycol has a molecular weight of about 20-45K.

7. The complex of claim 3, wherein the one or more polyalkylene glycols are two 20K polyethylene glycols.

8. The complex of claim 1, wherein the non-immunogenic, high molecular weight compound is attached to the PDGF nucleic acid ligand via a linker.

9. The complex of claim 7, wherein the two 20K polyethylene glycols are attached to the PDGF nucleic acid ligand via a linker.

10. The complex of claim 9, wherein formation of the linker comprises conjugating the following compound ##STR00003## to a 5' primary amino group of an aminolinker on the 5'-end of the PDGF nucleic acid ligand.

11. A complex having the structure A-B-Y, wherein A is one or more polyalkylene glycols, B is a linker, and Y is a PDGF nucleic acid ligand of SEQ ID NO:146, wherein N at positions 10 and 23 of SEQ ID NO:146 is ##STR00004##

12. The complex of claim 11, wherein each of the one or more polyalkylene glycols is polyethylene glycol.

13. The complex of claim 12, wherein the polyethylene glycol has a molecular weight of about 10-80 K.

14. The complex of claim 12, wherein the polyethylene glycol has a molecular weight of about 20-45K.

15. The complex of claim 11, wherein the one or more polyalkylene glycols are two 20K polyethylene glycols.

16. The complex of claim 11, wherein each of the one or more polyalkylene glycols (A) is attached to the spacer (B) via a linker.

17. A complex comprising a non-immunogenic, high molecular weight compound and a platelet derived growth factor (PDGF) nucleic acid ligand, wherein the nucleic acid ligand has the structure: ##STR00005## in which the N is ##STR00006##

18. The complex of claim 17, wherein the non-immunogenic, high molecular weight compound is a polyalkylene glycol.

19. The complex of claim 18, having one or more polyalkylene glycols.

20. The complex of claim 19, wherein each of the one or more polyalkylene glycols is polyethylene glycol.

21. The complex of claim 20, wherein the polyethylene glycol has a molecular weight of about 10-80K.

22. The complex of claim 20, wherein the polyethylene glycol has a molecular weight of about 20-45K.

23. The complex of claim 19, wherein the one or more polyalkylene glycols are two 20K polyethylene glycols.

24. The complex of claim 17, wherein the non-immunogenic, high molecular weight compound is attached to the PDGF nucleic acid ligand via a linker.

25. The complex of claim 23, wherein the two 20K polyethylene glycols are attached to the PDGF nucleic acid ligand via a linker.

26. The complex of claim 25, wherein formation of the linker comprises conjugating the following compound ##STR00007## to a primary amino group of an aminolinker on the 5'-end of the PDGF nucleic acid ligand.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc